Metagenomi Reports Business Updates and Full Year 2023 Financial Results [Yahoo! Finance]
Metagenomi, Inc. (MGX)
Company Research
Source: Yahoo! Finance
Proof of capability demonstrated with CRISPR-associated transposase (CAST) system being developed to enable 10,000 base pair, targeted genomic integrations Ultra-small base editing systems (SMART) are the smallest nickase-based systems characterized to-date, designed to enable more efficient delivery via single adeno-associated viruses (AAVs) Closing of initial public offering provides cash runway to support 2 INDs and 2 additional Development Candidate nominations EMERYVILLE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates. “We continue to execute across all aspects of our business. Throughout 2023, we achieved key therapeutic milestones, including preclinical proof of
Show less
Read more
Impact Snapshot
Event Time:
MGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGX alerts
High impacting Metagenomi, Inc. news events
Weekly update
A roundup of the hottest topics
MGX
News
- Metagenomi, Inc. (NASDAQ: MGX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Metagenomi, Inc. (NASDAQ: MGX) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $6.00 price target on the stock, down previously from $16.00.MarketBeat
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems [Yahoo! Finance]Yahoo! Finance
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systemsGlobeNewswire
- Metagenomi to Present at Upcoming Scientific MeetingsGlobeNewswire
MGX
Sec Filings
- 5/1/24 - Form 8-K
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- MGX's page on the SEC website